Urine test could lead to better treatment of bladder cancer

February 26, 2015

Researchers at the University of Birmingham believe that a simple urine test could help to guide clinicians in the treatment of bladder cancer patients.

Being able to reliably identify those patients with the most aggressive cancers early via , and expediting aggressive therapeutic strategies, may significantly improve outcomes. The scientists believe that the validation of two urinary biomarkers could spell a new way of tailoring treatment.

Patient management has changed little over the last three decades, so it is hoped that this research, published in British Journal of Cancer, will prove to be a step forward for the field with a view to providing improved care for each patient.

Dr Douglas Ward, from the University of Birmingham, explained, "There is an urgent need for prognostic biomarkers that could guide patient management. If such a test could be delivered, in a non-invasive way, it could make treatment much more efficient and that can only be a good thing."

Although a number of prognostic markers have been reported for bladder cancer, they are not currently used in the clinic. These markers are either based on nucleic acids (such as gene expression and mutation profiles) or protein expression levels; and as such require expensive and invasive analysis of tumour tissue via complex laboratory tests.

Previous research by the team used shotgun proteomics, a means of analysing the proteins in complex biological and clinical specimens, to identify the proteins released by cancer cell lines and generate candidate markers for developing a non-invasive urinary test.

This paper identified two prognostic urinary biomarkers, epidermal growth factor receptor (EGFR) and a protein, epithelial cell adhesion molecule (EpCAM), and validated them in over 400 clinical samples.

Both urinary EGFR and EpCAM were found to be independent predictors of bladder cancer-specific survival and have prognostic value over and above that provided by standard clinical and pathological observations. Higher levels of the biomarkers correlated with more aggressive cases of cancer and those with poor survival.

Measuring the biomarkers could therefore represent a simple and useful approach for fast-tracking the investigation and treatment of patients with the most aggressive bladder cancers.

Such tests would be useful in both newly-diagnosed patients and existing patients who receive a cystoscopic diagnosis of recurrence during surveillance.

Furthermore, identifying patients with the least aggressive disease may enable a refinement of surveillance strategies according to risk. It could mean reduced visits to a clinician, or even discharging patients from specialist care sooner than expected.

Mr Rik Bryan, from the University of Birmingham added, "These alone cannot be used to diagnose bladder cancer, but there is immense value in being able to easily and independently indicate the prognosis of the disease in order to guide treatment and decide whether more or less aggressive management is required."

Each year approximately 100,000 patients in the UK undergo investigation for haematuria, the cardinal symptom of . Around 10,000 of these patients are subsequently diagnosed, and 5,000 will ultimately die from the disease.

Urinary is one of the most expensive malignancies to manage on a per patient basis, with a total annual cost to the NHS of around £65m.

Explore further: Urine test could help detect aggressive bladder cancer

More information: British Journal of Cancer (2015), 1-7 | DOI: 10.1038/bjc.2015.21

Related Stories

Urine test could help detect aggressive bladder cancer

November 29, 2013
A simple urine test could distinguish between aggressive and less aggressive bladder cancers according to a new Cancer Research UK study published in the British Journal of Cancer.

New target for aggressive bladder cancer

July 10, 2014
An international team of scientists have discovered a faulty process in certain bladder cancers that could point to new ways to treat patients with an aggressive form of the disease.

MicroRNAs have diagnostic and prognostic potential in urinary bladder cancer

August 15, 2013
German researchers have identified four biomarkers that correctly determine malignancy of urinary bladder cancers and contribute to the accurate prediction of patient outcomes. Their results are published in the September ...

Scientists propose a breast cancer drug for bladder cancer patients

January 22, 2014
Researchers at Mayo Clinic have found amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC) and have shown that the presence of HER2 amplification ...

Researchers develop novel approach to visualize, measure protein complexes in tumors

January 15, 2015
Cancer diagnosis and treatment decisions are often hampered by a lack of knowledge of the biological processes occurring within the tumor. Moffitt Cancer Center researchers have developed a new approach to analyze these processes ...

Study could lead to 'liquid biopsy' tests for bladder cancer

January 22, 2014
Findings from a Loyola University Medical Center study ultimately could lead to tests to screen for and diagnose bladder cancer.

Recommended for you

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.